ORYL Photonics
Updating the operating model
- Biotechnology
- January 2026
A4BEE prepared this analysis from publicly available sources. It reflects our own reading of ORYL Photonics's published strategy and is not endorsed by, or produced in cooperation with, ORYL Photonics. Company website
Strategic priorities
ORYL Photonics operates across 4 stated priorities, with the most concrete near-term plan anchored on green lab strategies.
Commitment to environmental sustainability through patented laser light-scattering technology that reduces hazardous chemical consumption and scarce drug compound usage by 100x compared to traditional HPLC or nephelometry methods.
use over a decade of EPFL incubation to establish Second Harmonic Scattering (SHS) as the definitive industry reference for molecular-level sensitivity in solubility and aggregation measurement using the non-destructive Solvent Redistribution method.
Empowering pharmaceutical researchers to reach critical go/no-go decisions faster through high-throughput screening capabilities that can profile a full 384-well plate in under 15 minutes with nanomolar sensitivity.
-
01
Green Lab Strategies
Commitment to environmental sustainability through patented laser light-scattering technology that reduces hazardous chemical consumption and scarce drug compound usage by 100x compared to traditional HPLC or nephelometry methods.
-
02
Innovation through Light Scattering
use over a decade of EPFL incubation to establish Second Harmonic Scattering (SHS) as the definitive industry reference for molecular-level sensitivity in solubility and aggregation measurement using the non-destructive Solvent Redistribution method.
-
03
R&D Acceleration and Decision Intelligence
Empowering pharmaceutical researchers to reach critical go/no-go decisions faster through high-throughput screening capabilities that can profile a full 384-well plate in under 15 minutes with nanomolar sensitivity.
-
04
Commercial Scaling and SMaaS Evolution
Transitioning from asset-heavy hardware sales to a hybrid approach including Solubility Measurement as a Service (SMaaS) that enables global clients to access proprietary SHS technology without immediate capital expenditure.
Challenges we see
- Digital Integration
Laboratory Data Interoperability and the Paper Wall
As ORYL Photonics scales F1 hardware deployments and SMaaS offerings, high-fidelity SHS measurement data remains trapped within instrument-specific software ecosystems, creating data islands that prevent enterprise-wide analytics.
The reliance on manual data transcription and isolated spreadsheets introduces Process Blind Spots, with research indicating 57% of laboratory personnel struggle with sophisticated software integration, threatening regulatory compliance under GxP standards.
- Operations Manufacturing
Manufacturing Scale-up and Supply Chain Volatility
The transition from producing the ORYL Screener prototype to industrial-scale ORYL F1 rollout requires significant manufacturing process overhaul within a global ecosystem squeezed by sterile manufacturing capacity demands.
The BIOSECURE Act creates uncertainty for startups relying on international providers for specialized optical components, while maintaining stable supply chains for high-precision components and ensuring Day-1 commercialization readiness represents a high-risk friction point.
- Operations Labor
Workforce Skill Gap and Training Latency
Deployment of advanced laser-based metrology equipment like the ORYL F1 requires high technical literacy among end-users and technicians for proper operation and calibration.
Rapid automation introduces a Training Lag where the technical knowledge required to operate sophisticated SHS interfaces trails physical hardware deployment, threatening the brand promise of Results with Precision, with manual mistakes increasing by up to 30% without modern training interventions.
- Compliance Regulatory
Regulatory Pressure and Data Integrity Mandates
Operating in pharmaceutical and life science sectors necessitates strict adherence to evolving data integrity standards and Compliance by Design principles for the Facility of the Future model.
Current reliance on disparate data management practices creates vulnerability during regulatory submissions, where the inability to provide full data lineage from initial laser scattering event to final solubility report can lead to Quality incidents and lost investor confidence.
- Digital Financial
Infrastructure Obsolescence and Budget-Constrained Modernization
Many ORYL target clients are burdened with Legacy IT and MES Integration issues where outdated laboratory infrastructure cannot easily interface with modern high-speed metrology equipment.
Budget constraints often prioritize production over R&D modernization, creating a CapEx Barrier that traps R&D teams in low-efficiency cycles and slows adoption of the ORYL F1 in favor of slower, compound-heavy legacy technologies like HPLC.
Opportunities, by urgency and business impact
Each bubble is one opportunity, numbered to match the list below. Further right means it bites sooner; higher means a bigger effect on the business. A bigger bubble means a bigger implementation effort.
-
Excessive Compound Consumption and R&D Waste
Traditional solubility assays require 100x more Active Pharmaceutical Ingredients than the ORYL F1, consuming extremely scarce and expensive compounds during early-stage discovery while conflicting with Green Lab sustainability goals.
Implementation of ORYL non-destructive Second Harmonic Scattering technology enables detection of solubility limits with nanomolar sensitivity using only 2 microliters of stock solution, with 100% sample recovery enabling further kinetic studies or orthogonal testing.
-
Throughput Bottlenecks in Pre-clinical Screening
Conventional solubility measurement is a serial, slow process creating backlogs in pre-clinical screening facilities, with inability to rapidly profile candidates across various pH, buffer, and salt conditions delaying time-to-market.
Utilizing the ORYL F1 automated format fully compatible with 96 and 384 well-plates and robotics like Echo acoustic dispensers allows full plate processing in 15 minutes, enabling the high-throughput TechBio model where data collection keeps pace with automated synthesis.
-
Fragmented Data Ecosystems and Dark Data
Critical R&D data from metrology instruments is recorded on paper or isolated spreadsheets, leading to Dark Data that cannot be utilized for predictive modeling or AI-driven Golden Batch optimization.
Developing a Source-to-Scientist data work through integration of the ORYL F1 with ontology-based data platforms ensures data integrity and allows application of AI/ML algorithms to predict solubility outcomes before physical experiments are completed.
-
Training Inefficiency and Human Error
Manual reliance on visual colony counting, pipetting, and operation of complex laser optics introduces human error and limits throughput, while traditional training for sophisticated systems is slow and creates onboarding latency.
Deploying AR/VR immersive training environments and human-centric UX design can reduce manual mistakes by 30% while building Digital Lab environments that accelerate technician readiness and ensure consistent precision across global SMaaS hubs.
-
Legacy Infrastructure Integration Barriers
Target clients operate aging laboratory infrastructure that cannot interface with modern high-speed metrology, while budget constraints prevent R&D modernization investments necessary for ORYL F1 adoption.
Providing IoT retrofitting solutions and vendor-agnostic middleware enables connection of legacy equipment to modern data platforms, demonstrating quantified business cases that justify the shift from doing digital to being digital.
What we'd propose
- Enterprise AI
Digital Lab Ecosystem and bioprocess Control Integration
Unifying the ORYL F1 hardware with laboratory IT infrastructure via a vendor-agnostic middleware layer to eliminate data silos and automate GxP-compliant reporting from sensor to scientist.
-
Ontology layer
DETAIL
-
Predictive models
DETAIL
-
Decision surfaces
DETAIL
- Shorter lead time from data capture to decision.
- Records that audit on their own, not on inspection day.
- Scale without adding the same headcount.
-
- Digital CDMO
IoT Retrofitting and Asset Performance Management
Equipping ORYL F1 units and auxiliary laboratory assets with hardware-agnostic IoT gateways to enable real-time connectivity, centralized monitoring, and predictive maintenance across distributed SMaaS hubs.
-
OT/IT convergence
DETAIL
-
Batch intelligence
DETAIL
-
Production release flow
DETAIL
- Shorter lead time from data capture to decision.
- Records that audit on their own, not on inspection day.
- Scale without adding the same headcount.
-
- Digital Lab
Immersive AR/VR Training and Remote Guidance
Building realistic virtual environments and augmented reality overlays for safe, rapid technician training on complex SHS systems, HPAPI handling, and remote expert support across global SMaaS operations.
-
Unified data backbone
DETAIL
-
Paperless workflows
DETAIL
-
Continuous QC release
DETAIL
- Shorter lead time from data capture to decision.
- Records that audit on their own, not on inspection day.
- Scale without adding the same headcount.
-
- Digital Lab
AI-Driven Vision Systems for Advanced Metrology
Deploying camera-based machine learning algorithms to automate precipitate detection, crystallization classification, and quality verification, complementing SHS measurements with real-time visual analytics.
-
Unified data backbone
DETAIL
-
Paperless workflows
DETAIL
-
Continuous QC release
DETAIL
- Shorter lead time from data capture to decision.
- Records that audit on their own, not on inspection day.
- Scale without adding the same headcount.
-
- Digital Lab
Vendor-Agnostic Legacy Infrastructure Modernization
Providing comprehensive assessment and modernization pathways for legacy laboratory infrastructure, enabling smooth ORYL F1 integration and demonstrating quantified ROI to overcome CapEx barriers.
-
Unified data backbone
DETAIL
-
Paperless workflows
DETAIL
-
Continuous QC release
DETAIL
- Shorter lead time from data capture to decision.
- Records that audit on their own, not on inspection day.
- Scale without adding the same headcount.
-
Digital maturity: today and target
Scored out of 100 across six dimensions. The target is what ORYL Photonics's own published ambition implies — not a perfect score.
- Data Interoperability 30 → 90
- SHS measurements from F1 are not yet integrated into automated Source-to-Scientist pipelines, with data remaining in instrument-specific silos
- Workforce Readiness 40 → 85
- Documented 57% skill gap in biotech for sophisticated digital systems requires digital-native mindset and AR/VR-enabled training programs
- Process Intelligence 35 → 80
- Current R&D relies heavily on manual tasks creating blind spots during scaling, target requires AI-driven predictive modeling for Golden Batch
- Asset Connectivity 45 → 95
- While F1 is modern, auxiliary legacy equipment in SMaaS hubs remains air-gapped, target requires full real-time visibility via IoT gateways
- Regulatory Compliance 50 → 90
- Compliance is currently reactive and paper-heavy, target state requires Compliance-by-Design with automated GxP-compliant cloud audit trails
- Sustainability Reporting 55 → 90
- ORYL supports Green Lab strategies but lacks unified platform to quantify chemical and compound savings for sustainability disclosures
Check this yourself
Our Service Portal has free self-assessments and market comparisons. These are the ones that line up with what we've read above — no sales call required.
-
Self-assessment
Data & AI Maturity
See how ready your data actually is for the AI work you're planning.
-
Self-assessment
Electronic Batch Record (eBR) Readiness
Check how far your batch records are from paperless, and what the next step is.
-
Market comparison
Pharma Data Platform Use Cases — Ranked
Use cases ranked by how hard they are against what they're worth.
-
Market comparison
European CDMOs Compared
The 2026 landscape: who does what, at what scale.
Think we've read this right?
Talk to usRelated reading
-
Still biotech or already techbio?
The results of a Tech Imperatives for biotech 2022 report indicate changes in biotech production and management.
-
Biotech and Pharma cloud use cases
Cloud computing is quickly becoming more and more popular among biotech and pharma companies. Harness gains, no pains, and read use cases!
-
Lab of Tomorrow: We’re at a Turning Point – Is Your Lab on the Right Track?
Do you know what the biggest paradox is? Biotech and pharma fully understand that digitization is the future. Most of them know that effective market competition is simply not possible without artificial intelligence, automation, and data analysis. And yet, many labs are still stuck in the past, working in isolation, manually analyzing data, and losing the potential that technology offers.
-
From Paper to Performance: Operational Efficiency and Compliance in Labs
Transform your QC lab with scalable digital solutions that embed compliance, boost efficiency, and deliver a future-ready competitive edge.
-
Lab Automation. Delivering Solutions and Future Directions.
The benefits of automating processes in labs combined with modern IT technologies are far beyond just making actions and collecting data.
This is an independent analysis prepared by A4BEE from publicly available information as of January 2026. It reflects A4BEE's own interpretation and opinion, is not affiliated with, endorsed by, or verified with ORYL Photonics, and may be incomplete or inaccurate. All company names and trademarks are the property of their respective owners. To request a correction or removal, contact [email protected].